News

TipRanks on MSN3h

Summit Therapeutics price target raised to $33 from $30 at Clear Street

Clear Street raised the firm’s price target on Summit Therapeutics (SMMT) to $33 from $30 and keeps a Buy rating on the shares following the Q2 ...

Clear Street Reaffirms Their Buy Rating on Intuitive Machines (LUNR)

Detailed price information for Intuitive Machines Inc (LUNR-Q) from The Globe and Mail including charting and trades.

McKinley Acquisition Corp Announces Pricing of $150 Million Initial Public Offering

McKinley Acquisition Corporation (the “Company”), announced the pricing of its initial public offering of 15,000,000 units at ...

McKinley Acquisition Corporation: McKinley Acquisition Corp Announces Pricing of $150 Million Initial Public Offering

McKinley Acquisition Corporation (the "Company"), announced the pricing of its initial public offering of 15,000,000 units at $10.00 per unit, with each ...

Arq outlines path to 25M lb GAC capacity within 6 months amid PAC strength and Phase 2 expansion plans

PAC business momentum continued, with ongoing ASP growth (9% in Q2 vs. 13% in Q1), but gross margin decreased to 33% from 36.4% due to commissioning-related costs. SG&A declined further, while R&D ...
TipRanks on MSN6h

Novartis ianalumab Phase III trial meets primary endpoint in ITP

Novartis (NVS) announced positive top-line results from VAYHIT2, a Phase III trial evaluating ianalumab plus eltrombopag in patients with primary ...